Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
This finding was especially pronounced among those with cirrhosis, a history of depression, liver disease progression or liver cancer.
The CDC has released a new hepatitis A surveillance report.
Just over half of people who use drugs in eight cities are hepatitis C virus antibody positive.
Such a vaccine would make inoculation easier in developing nations, where the need is great.
This is compared with providing people who inject drugs with hep C drugs to take independently.
Bulevirtide plus pegylated interferon shows promise for hard-to-treat coinfection.
The approval applies to those between 12 and 17 years old who have any of the six genotypes of the virus.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
Selonsertib did not improve liver fibrosis more than a placebo.
The World Health Organization has set various benchmarks for nations to hit in controlling their epidemics by 2030.
The nation has provided unrestricted access to hepatitis C treatment since 2016.
Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.
The spray requires no medical training.
Curing the virus was associated with a lower risk of liver cancer recurrence.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.